Publications by authors named "Alena Machell"
Introduction: Oral semaglutide provides an alternative to injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment of type 2 diabetes (T2D). The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide treatment of T2D in a real-world setting. PIONEER REAL UK focused on adults living with T2D in the UK.
View Article and Find Full Text PDFArticle Synopsis
- OW semaglutide significantly improved glycemic control and body weight in adults with type 2 diabetes (T2D) in the real-world SURE UK study, confirming findings from prior SUSTAIN trials.
- The study measured the change in glycated hemoglobin (HbA) and found an average reduction of -16.3 mmol/mol and a mean body weight reduction of -5.8 kg over approximately 30 weeks.
- No new safety issues were reported, supporting the ongoing use of OW semaglutide in clinical practice for T2D management.